Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 1/2 2Phase EARLY_PHASE1 1Phase 4 1

Status

Completed 3

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Dermatologic 2

Conditions

Multiple Myeloma 129Recurrence 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Neoplasms, Plasma Cell 15Neoplasms 12Lymphoma, Non-Hodgkin 12Lymphoma 12Leukemia, Myeloid, Acute 10Lymphoma, Large B-Cell, Diffuse 9Neoplasm Metastasis 8Leukemia 8Burkitt Lymphoma 8Immunoglobulin Light-chain Amyloidosis 7Hodgkin Disease 7Prostatic Neoplasms 6Leukemia, Biphenotypic, Acute 5Lymphoma, B-Cell 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hematologic Neoplasms 4Waldenstrom Macroglobulinemia 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, T-Cell 3Lymphoma, Follicular 3Hematologic Diseases 3Colorectal Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 2Sarcoma 2Rectal Neoplasms 2

Interventions

Cyclophosphamide 8Vincristine 6romidepsin 5Prednisone 5Doxorubicin 5Lenalidomide 4Etoposide 4fludarabine phosphate 3fludarabine 3Rituximab 3Dexamethasone 3Bortezomib 3Azacitidine 3selinexor 2darinaparsin 2carfilzomib 2belinostat 2Oxaliplatin 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Ipilimumab 2Injections 2Gemcitabine 2Depsipeptides 2Dasatinib 2Carboplatin 2CTLA-4 Antigen 2Brentuximab Vedotin 2Biopsy 2Bendamustine Hydrochloride 2Alemtuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, T-Cell, Peripheral × Dexamethasone × Clear all
NCT01846390 2026-03-27

Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma

Canadian Cancer Trials Group

Phase 1 Completed
21 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 24 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT02181218 2020-11-17

Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas

Washington University School of Medicine

Phase 1 Completed
24 enrolled
DermatologicLymphoid

Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡